Controlling Prostate Cancer Through Durable Inhibition of Androgen Receptor Activity

The great majority of prostate cancers remain dependent on effective activity of the androgen receptor – even cancers that no longer respond to androgen-antagonist measures and hence are characterized as “androgen-independent”. It may however prove feasible to durably inhibit androgen receptor activity with specially targeted drugs now being developed, while suppressing expression of the androgen receptor with measures that suppress activity of the pro-inflammatory transcription factor NF-kappaB.

Click to download